The FDA Approved Revolution Medicines' First Drug. The Market Was Already Paying for It.

The FDA this morning approved daraxonrasib — sold as RASONQUE — the first drug of its kind for the most common form of pancreatic cancer, and Revolution Medicines' stock barely moved. Up less than 1% as of this writing, a quiet day for a company that just turned its first-ever product into an approved product, worth about $45.5 billion. That flatness is the story, sort of.

Start with the arithmetic. The stock has risen about 168% this year and sits near its 52-week high of roughly $220 after trading below $38 a year ago. The market did not need to be told the drug worked. It had the data in April, when Revolution announced that in a 500-patient randomized Phase 3 trial against chemotherapy in previously treated metastatic pancreatic cancer, daraxonrasib roughly doubled survival — a median overall survival of 13.2 months versus 6.6 months in the RAS G12-mutant population, a 60% reduction in the risk of death, with tumors shrinking in about a third of patients versus about 12% on chemo. The trial's results were later published in the New England Journal of Medicine and presented at an ASCO plenary session. Today's FDA approval is the formality that turns those numbers into a product.

So why does the flat approval day matter? Because it tells you what the market has been paying for — and it was not paying for today's news. It has been paying, for months, for a mechanism.

Pancreatic cancer has one defining feature: a mutated KRAS gene. About nine in ten pancreatic tumors carry it. For decades that made the disease effectively "undruggable," because KRAS is a protein everyone assumed you couldn't get a drug molecule into. Then came the first generation of KRAS drugs — sotorasib and adagrasib — and they worked, but only against one specific mutation, called G12C, which shows up in a small slice of pancreatic cancer. The commercial problem was the classification: a huge disease, and each drug only reached a sliver of it.

Daraxonrasib is a different animal. Instead of targeting one mutant copy, it grabs the active, "on" form of RAS itself — with help from a cellular protein called cyclophilin A — and that grip covers most of the mutation families that actually occur, the G12, G13, and Q61 variants, as well as healthy RAS caught in the "on" position. One pill, most of the mutations. That is the "broad RAS" in the headlines, and it is the economic core of the company: the addressable population goes from a sliver to a majority.

Here is where the label and the mechanism part ways, and that gap is the investment question. The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have already had one prior systemic therapy, or who aren't candidates for multi-drug chemotherapy. That is a narrow grant on a broad mechanism: the sickest, most heavily treated slice of the disease, where the prior standard was a few months of extra life. Doctors win this one. Months of life nearly doubled in a disease that kills nearly everyone it touches, with side effects that are nasty — a rash in 85% of patients, plus mouth sores and diarrhea — but generally better tolerated than chemotherapy.

For the shareholder, the earlier framing is what matters. Wall Street analysts expect the drug's annual sticker price to reach several hundred thousand dollars; one independent model prices it at $200,000 a year net. But this is a niche population — the roughly 67,000 new pancreatic cancer cases the U.S. sees each year, winnowed down to those whose disease has advanced past first-line chemo — treated for a median of perhaps a year. Even the most generous version of the whole pancreatic opportunity, across every line of therapy and including trials that haven't read out yet, is penciled at roughly $5 billion to $8.5 billion in peak annual sales. Analysts' consensus on the franchise is $5–7.6 billion; the independent bottom-up estimate is $8.5 billion.

Now do the multiplication. A $45 billion company, one approved product, and a total pancreatic franchise that even generous models cap around $8.5 billion at peak. No reasonable multiple of peak pancreatic sales gets you to $45 billion on its own. The rest of the market capitalization is a stake in the rest of the platform: daraxonrasib moving into first-line pancreatic cancer and the roughly 30% of lung cancer patients whose tumors harbor RAS mutations — by far the biggest RAS market — plus a separate G12D-selective drug, zoldonrasib, that has its own Phase 3 program. The approvals you read about today are the first domino. The valuation is the price of the whole domino set, most of which hasn't fallen yet, or even been started.

The money side is worth understanding too, because it tells you who is taking the risk. Revolution is not partnering this drug out the door; it kept the rights and is spending heavily to go it alone — building its own commercial and manufacturing organization, and running eight or more global Phase 3 trials at once. It ended June with $3.9 billion in cash, assembled with a roughly $1.7 billion equity offering in April, convertible notes, and the first tranche of a Royalty Pharma arrangement that can deliver up to $1.5 billion more against future drug royalties. The structure is worth pausing on: Royalty Pharma writes checks now, with milestones, in exchange for a claim on the eventual sales stream. That is the financing model in a nutshell — capital for a share of revenue, no strategic partner calling the shots.

The burn is the other side of that sentence. The second quarter net loss was $644 million, and the company guided to operating expenses of $2.1 billion to $2.2 billion for 2026 before non-cash stock comp. At that pace, the cash on hand is roughly two years of runway, a bit more if the Royalty Pharma tranches come through — which means the next two years of clinical readouts are happening on a clock. Revenue starts now, but it starts from zero, and the near-term revenue from a niche label is a bridge, not the value.

The risks are the ordinary ones for a company priced like this, with one twist. The obvious risks: tolerability of a chronic pill that gives 85% of patients a rash, which is a real question for the combination studies that are the whole next act; and competition, which is filling in on both flanks. The pan-RAS lane is the least crowded place in oncology right now, and daraxonrasib is its leader. But the G12C lane behind it is packed with better drugs — Roche's divarasib posted strong, possibly best-in-class lung-cancer data in July, joining Amgen, Bristol Myers, Lilly, and Merck. And the G12D lane, the single most common KRAS mutation in pancreatic cancer, is filling up too: Incyte has a G12D candidate with early clinical data, Astellas has a degrader in late-stage testing, and more are on the way.

The twist is that Revolution is competing with itself. Its G12D-selective drug, zoldonrasib, is in Phase 3 against some of the same patients that daraxonrasib would treat, and its G12C drug, elironrasib, is in Phase 3 in lung cancer. That is hedging by design — place two bets on the same target and let the trials sort out who wins. It is also, structurally, a plan to split your own pie. The next big valuation events are 2027, when the first-line pancreatic and lung-cancer readouts land; until then, the stock trades on the launch — what price gets set, how the more than 2,000 patients already on the drug through an expanded-access program convert into billable revenue, and whether the pipeline keeps hitting.

The approval is a genuine medical event, and it validates the core idea that one molecule can cover the mutation that dominates one of the deadliest common cancers. But it is not news the stock needed to hear, and the market's reaction — roughly nothing — is the honest verdict on that. The useful discipline with a stock like this is to keep the two questions apart: is this great news, and is this news the price already contains? Today, the answer to the first is yes, and the answer to the second is no — it was in the price months ago. The $45 billion price tag is now simply a statement of what the next two years have to deliver: whether the franchise outgrows the label, and whether any of it survives contact with competition.